Sanofi (SNY) Posts In-Line Q2 Earnings, Revenues Down Y/Y
Zacks Equity Research - Zacks Investment Research - 2 hrs 53 mins ago
Sanofi (SNY) reported second-quarter 2016 business earnings of 74 cents per American Depositary Share, in line with the Zacks Consensus Estimate.
ZTS: 50.40 (-0.07), INVA: 13.04 (+0.17), ANIP: 61.06 (+0.46), SNY: 42.49 (-0.14)
Integra (IART) Tops Q2 Earnings, Grows Organically, Ups View
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 3:05PM CDT
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share (EPS) of 79 cents in the second quarter of 2016.
IART: 84.59 (+0.32), FCSC: 1.02 (-0.07), ANIP: 61.06 (+0.46), ANIK: 50.64 (+0.72)
GoDaddy (GDDY) Q2 Earnings Likely to Beat: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 10:09AM CDT
We expect GoDaddy Inc. (GDDY) to beat expectations when it reports second-quarter 2016 results on Aug 3. Whether a likely beat drives the company's share price will be interesting to watch.
BTG: 3.18 (+0.05), ANIP: 61.06 (+0.46), HL: 6.60 (+0.11), GDDY: 30.34 (+0.42)
Can DENTSPLY (XRAY) Spring an Earnings Surprise in Q2?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:15AM CDT
DENTSPLY SIRONA Inc. (XRAY) is expected to report second-quarter 2016 results on Aug 5.
GNVC: 0.61 (+0.02), ANIP: 61.06 (+0.46), XRAY: 64.23 (+0.19), COO: 182.61 (+0.14)
Will TrovaGene (TROV) Pull an Earnings Surprise in Q2?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:11AM CDT
TrovaGene Inc. (TROV) is expected to release second-quarter 2016 results on Aug 4.
ZTS: 50.40 (-0.07), TROV: 5.58 (-0.05), ANIP: 61.06 (+0.46), GLYC: 8.84 (+0.49)
Inogen (INGN) Q2 Earnings: Can the Stock Pull a Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:54AM CDT
Inogen Inc. (INGN) is scheduled to report second-quarter 2016 results on Aug 4.
ZTS: 50.40 (-0.07), ANIP: 61.06 (+0.46), INGN: 53.00 (-0.74), GLYC: 8.84 (+0.49)
Pacific Biosciences (PACB) Q2 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:52AM CDT
Pacific Biosciences of California Inc. (PACB) is scheduled to report second-quarter 2016 results on Aug 4.
ZTS: 50.40 (-0.07), PACB: 8.62 (+0.07), ANIP: 61.06 (+0.46), GLYC: 8.84 (+0.49)
Can Cerner (CERN) Spring a Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:45PM CDT
Cerner Corporation (CERN) is expected to report second-quarter 2016 results on Aug 2.
ANIP: 61.06 (+0.46), GLYC: 8.84 (+0.49), NKTR: 17.76 (+0.47), CERN: 62.22 (-0.17)
Cardinal Health (CAH) Q4 Earnings: Disappointment in Store?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:01PM CDT
Cardinal Health Inc. (CAH) is set to report fourth-quarter fiscal 2016 earnings results on Aug 2.
ANIP: 61.06 (+0.46), CAH: 82.41 (-1.19), GLYC: 8.84 (+0.49), NKTR: 17.76 (+0.47)
Aetna (AET) Poised to Beat on Earnings in Q2: Here's Why
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 10:34AM CDT
Our proven model shows that Aetna (AET) is likely to beat on earnings in the second quarter.
ANIP: 61.06 (+0.46), GALE: 0.45 (+0.01), AET: 114.45 (-0.76), HUM: 171.18 (-1.37)
Alkermes (ALKS) Posts Narrower Q2 Loss, Ups 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 10:06AM CDT
Alkermes (ALKS) reported a narrower-than-expected, second-quarter 2016 loss while revenues beat estimates; the company revised its outlook for 2016.
INVA: 13.04 (+0.17), FCSC: 1.02 (-0.07), ANIP: 61.06 (+0.46), ALKS: 49.56 (-0.34)
Agenus (AGEN) Posts Narrower than Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:47AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 24 cents per share, narrower than the Zacks Consensus Estimate of a loss of 34 cents.
AGEN: 5.65 (+0.10), ANIP: 61.06 (+0.46), MRK: 58.66 (unch), NKTR: 17.76 (+0.47)
Can PerkinElmer (PKI) Pull a Surprise this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:24AM CDT
PerkinElmer Inc. is expected to report second-quarter 2016 results on Aug 4.
ANIP: 61.06 (+0.46), GLYC: 8.84 (+0.49), PKI: 56.69 (-0.23), HUM: 171.18 (-1.37)
AstraZeneca (AZN) Beats on Q2 Earnings, Keeps 2016 View
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:16AM CDT
AstraZeneca (AZN) reported second-quarter 2016 core earnings of 83 cents per American Depositary Share, beating the Zacks Consensus Estimate of 42 cents.
INVA: 13.04 (+0.17), ANIP: 61.06 (+0.46), AZN: 33.84 (-0.30), NKTR: 17.76 (+0.47)
Becton, Dickinson (BDX) Q3 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:01AM CDT
Becton, Dickinson and Company (BDX) is set to report third-quarter fiscal 2016 earnings results on Aug 4.
BDX: 176.78 (+0.78), ANIP: 61.06 (+0.46), GLYC: 8.84 (+0.49), NKTR: 17.76 (+0.47)
Fate Therapeutics (FATE) Catches Eye: Stock Rises 5.9%
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 7:15AM CDT
Fate Therapeutics, Inc. (FATE) was a big mover last session, as its shares rose almost 6% on the day.
FATE: 1.99 (-0.08), ANIP: 61.06 (+0.46)
Eleven Biotherapeutics (EBIO) Jumps: Stock Rises by 10.4%
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 7:00AM CDT
Eleven Biotherapeutics, Inc. (EBIO) was a big mover last session, as the company saw its shares rise over 10% on the day.
EBIO: 3.80 (-0.17), ANIP: 61.06 (+0.46)
Celgene (CELG) Tops Q2 Earnings & Revenues, Lifts View
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 11:11AM CDT
Celgene (CELG) reported better-than-expected second-quarter 2016 earnings and revenues; it once again raised the earnings outlook for 2016.
INVA: 13.04 (+0.17), FCSC: 1.02 (-0.07), ANIP: 61.06 (+0.46), CELG: 114.69 (+2.50)
Alexion (ALXN) Tops Q2 Earnings and Revenues (Revised)
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 10:33AM CDT
Alexion's (ALXN) second-quarter 2016 earnings of 93 cents per share surpassed the Zacks Consensus Estimate of 91 cents.
INVA: 13.04 (+0.17), ANIP: 61.06 (+0.46), ALXN: 133.50 (+4.90), NKTR: 17.76 (+0.47)
Glaxo (GSK) Beats Q2 Earnings Estimates, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:59AM CDT
Glaxo (GSK) reported second-quarter 2016 core earnings of 70 cents per American depositary share, beating the Zacks Consensus Estimate of 55 cents.
INVA: 13.04 (+0.17), ANIP: 61.06 (+0.46), GSK: 45.25 (+0.18), NVS: 83.07 (-0.19)